Dasatinib is a potent multikinase inhibitor of second generation approved, in June 2006, by the FDA for the treatment of chronic myeloid leukemia (CML) and Philadelphia positive subtype of acute lymphoblastic leukemia (Ph+ ALL) patients, given its high potential to inhibit BCR-ABL and turn off its aberrant signaling in this pathology [127]. Here, BCR is linked to acute lymphoblastic leukemia.